Bill Oxford
Trinity Biotech (NASDAQ:TRIB) stock shot up 44% in post-market buying and selling Monday after the diagnostics firm increased its 2024 gross sales steering and mentioned it was ramping up manufacturing capacity.
Trinity mentioned that because of increased demand, it has expanded manufacturing capacity for its TrinScreen HIV check and raised its 2024 gross sales forecast for the product to $10M from $8M.
The firm has additionally increased manufacturing capacity for its FlexTrans viral transport medium because of an anticipated enhance in demand because of the mpox outbreak, in response to an announcement.
The World Health Organization just lately declared mpox, also referred to as monkeypox, a public well being emergency of worldwide concern amid the emergence of a extra simply transmissible variant of the virus.
Mpox vaccine builders embody Tonix Pharmaceuticals (TNXP), Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY) and GeoVax Labs (GOVX), whereas Emergent Biosciences (EBS) has an accredited vaccine and therapy for smallpox, a associated illness.
Providers of mpox check services embody LabCorp (LH), Quest Diagnostics (DGX), Co-Diagnostics (CODX), Roche (OTCQX:RHHBY), Abbott Laboratories (ABT) and Applied DNA Sciences (APDN).
Source: Seekingalpha